Emerging concepts in dendrimer-based nanomedicine: From design principles to clinical applications

Journal of Internal Medicine

Volumn 276, Issue 6, 2014, Pages 579-617

  Kannan, R M ^a   Nance, E ^b   Kannan, S ^b   Tomalia, D A ^c,d,e  

^a Department of Ophthalmology   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NanoSynthons   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Critical nanoscale design parameters; Dendrimers; Drug delivery; Nanomedicine; Nanoperiodic concept

Indexed keywords

COMPLEMENTARY DNA; DENDRIMER; FUNCTIONAL GROUP; GEMCITABINE; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLYAMIDOAMINE; POLYMER; PROTEIN DERIVATIVE; SMALL INTERFERING RNA;

ADVANCED CANCER; BACTERIAL INFECTION; BIOACCUMULATION; BREAST CANCER; CHEMICAL STRUCTURE; CONCEPTUAL FRAMEWORK; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; EYE DISEASE; HUMAN; MALIGNANT NEOPLASM; MELANOMA; METASTATIC BREAST CANCER; MYCOSIS; NANODEVICE; NANOENGINEERING; NANOMEDICINE; NANOTOXICOLOGY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; ONCOLOGY; PANCREAS CANCER; PARASITOSIS; PARTICLE SIZE; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; REVIEW; SURFACE PROPERTY; THERANOSTIC NANOMEDICINE; TISSUE INTERACTION; VIRUS INFECTION; WOUND HEALING; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DESIGN; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DENDRIMERS; DRUG APPROVAL; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NANOMEDICINE;

EID: 84911990896     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12280     Document Type: Review

References (228)

1. Ventola CL. The nanomedicine revolution, part 3: regulatory and safety challenges. Pharm Ther 2012; 37: 632-9.
2. Fadeel B, Kasemo B, Malmsten M, Strømme M. Nanomedicine: reshaping clinical practice. J Intern Med 2010; 267: 2-8.
3. Duncan R, Ringsdorf H, Satchi-Fainaro R. Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities. J Drug Target 2006; 14: 337-41.
4. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Appl Polym Sci Symp 1975; 51: 135-53.
5. Duncan R. The dawning era of polymer therapeutics. Nature Rev 2003; 2: 347-60.
6. Nijhara R, Balakrishnan K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine 2006; 2: 127-36.
7. Tyner K, Sadrieh N. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Methods Mol Biol 2011; 697: 17-31.
8. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) 2007; 2: 789-803.
9. Cai X, Hu J, Xiao J, Cheng Y. Dendrimer and cancer: a patent review (2006-present). Expert Opin Ther Pat 2013; 23: 515-29.
10. Bawa R. Regulating nanomedicine - can the FDA handle it? Curr Drug Deliv 2011; 8: 227-34.
11. Bellare JR. Nanotechnology and nanomedicine for healthcare: challenges in translating innovations from bench to bedside. J Biomed Nanotechnol 2011; 7: 36-7.
12. Wagner V, Dullaart A, Bock A, Zweck A. The emeging nanomedicine landscape. Nat Biotechnol 2006; 24: 1211-7.
13. Bamrungsap S, Zhao Z, Chen T et al. Nanotechnology in therapeutics. Nanomedicine (Lond) 2012; 7: 1253-71.
14. Valencia PM, Hanewich-Hollatz MH, Gao W et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 2011; 32: 6226-33.
15. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47: 113-31.
16. Tomalia DA et al. U.S. Patents: 5714166 (1998); 6224898 (2001); 6475994 (2002); 6471968 (2002); 7005124 (2006).
17. Kim BYS, Rutka JT, Chan WCW. Nanomedicine. N Engl J Med 2010; 363: 2434-43.
18. Christensen JB, Tomalia DA. A proposed taxonomy and classification strategy for well-defined, soft-matter nanoscale building blocks. In: Tomas T, Bottari G, eds. Organic Nanomaterials: Synthesis, Characterization, and Device Applications. Hoboken, NJ: John Wiley & Sons, 2013; 1-32.
19. Tomalia DA, Naylor AM, Goddard WA III. Starburst dendrimers: molecular level control of size, shape, surface chemistry, topology and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 1990; 29: 138-75.
20. Tomalia DA. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 2009; 11: 1251-310.
21. Tomalia DA. Dendrons/Dendrimer: quantized, nano-element like building blocks for soft-soft and soft-hard nano-compound synthesis. Soft Matter 2010; 6: 456-74.
22. Tomalia DA, Christensen JB, Boas U. Dendrimers, Dendrons, and Dendritic Polymers: Discovery, Applications and the Future. New York, NY: Cambridge University Press, 2012.
23. Tomalia DA, Khanna SN. In quest of a systematic framework for unifying and defining nanoscience. Mod Phys Lett B 2014; 28: 1430002-1-47.
24. Goodsell DS. Bionanotechnology. Hoboken, NJ: J. Wiley & Sons, 2004.
25. Joyce GF. Directed molecular evolution. Sci Am 1992; 267: 90-7.
26. Joyce GF. The antiquity of RNA-based evolution. Nature 2002; 418: 214-21.
27. Tomalia DA, Christensen JB, Boas U, eds. The dendritic effect. In: Dendrimers, Dendrons, and Dendritic Polymers: Discovery, Applications and the Future. New York, NY: Cambridge University Press, 2012; 276-92.
28. Christensen JB, Tomalia DA. Dendrimers as quantized nano-modules in the nanotechnology field. In: Designing Dendrimers. Hoboken, NJ: John Wiley & Sons, 2012; 1-33.
29. Yamamoto K, Imaoka T. Precision synthesis of subnanoparticles using dendrimers as a superatom synthesizer. Acc Chem Res 2014; 47: 1127-36.
30. Kemsley J. Developing superatom science. Chem Eng News 2013; 2013: 24-5.
31. Klug A. Tobacco mosiac virus particle structure and the initiation of disassembly. Phil Trans R Soc Lond B 1999; 354: 531-5.
32. Klug A. From macromolecules to biological assemblies (Nobel lecture). Angew Chem Int Ed 1983; 22: 565-82.
33. Scheinberg DA, Villa CH, Escorcia FE, McDevitt MR. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev 2010; 7: 266-76.
34. Wijagkanalan W, Kawakami S, Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res 2011; 28: 1500-19.
35. Iyer M, Mishra R, Han Y, Hopfinger AJ. Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis. Pharm Res 2002; 19: 1611-21.
36. Giri J, Diallo MS, Simpson AJ, Goddard WA III, Kumar R, Woods GC. Interactions of poly(amidoamine) dendrimers with human serum albumin: Binding constants and mechanisms. ACS Nano 2011; 5: 3456-68.
37. Pavan GM, Danini A. The influence of dendron's architecture on the "rigid" and "flexible" behaviour in binding DNA-a modelling study. Phys Chem Chem Phys 2010; 1: 13914-7.
38. Tian W, Ma Y. Theoretical and computational studies of dendrimers as delivery vectors. Chem Soc Rev 2013; 42: 705-27.
39. Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc Chem Res 2013; 46: 622-31.
40. Meng H, Yang S, Li Z et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano 2011; 5: 4434-47.
41. Alber F, Dokudovskaya S, Veenhoff LM et al. The molecular architecture of the nuclear pore complex. Nature 2007; 450: 695-701.
42. Gil PR, Oberdorster G, Elder A, Puntes V, Parak WJ. Correlating physico-chemical with toxicological properties of nanoparticles: the present and the future. ACS Nano 2010; 4: 5527-31.
43. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticles pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012; 52: 481-503.
44. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
45. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007; 35: 61-7.
46. Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25: 1165-70.
47. Burns AA, Vider J, Ow H et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett 2009; 9: 442-8.
48. Longmire MR, Ogawa M, Choyke PL, Kobayashi H. Dendrimers as high relaxivity MR contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2014; 6: 155-62.
49. Hamad I, Al-Hanbali O, Hunger AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010; 4: 6629-38.
50. Walczyk D, Bombelli BB, Monopoli MP, Lynch I, Dawson KA. What the cell "sees" in bionanoscience. J Am Chem Soc 2010; 132: 5761-8.
51. Kelly CV, Liroff MG, Triplett LD et al. Stoichiometry and structure of poly(amidoamine) dendrimer-lipid complexes. ACS Nano 2009; 3: 1886-96.
52. Pan Y, Neuss S, Leifert A et al. Size-dependent cytoxocity of gold nanoparticles. Small 2007; 3: 1941-9.
53. Cabral H, Matsumoto Y, Mizuno K et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011; 6: 815-23.
54. Mayer LD, Tai LCL, Ko DSC et al. Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989; 49: 5922-30.
55. Tang L, Gabrielson NP, Uckun FM, Fan TM, Cheng J. Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates. Mol Pharm 2013; 10: 883-92.
56. Yue J, Liu S, Xie Z, Xing Y, Jing X. Size-dependent biodistribution and antitumor efficacy of polymer micelle drug delivery systems. J Mater Chem B 2013; 1: 4273-80.
57. Zou YY, Ling YH, Reddy ST, Priebe W, Perezsoler R. Effect of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int J Cancer 1995; 61: 666-71.
58. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010; 7: 1195-208.
59. Tang L, Fan TM, Borst LB, Cheng JJ. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. ACS Nano 2012; 6: 3954-66.
60. Adjei IM, Peetla C, Labhasetwar V. Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine 2014; 9: 267-78.
61. Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater 2013; 12: 958-62.
62. Lee CA, MacKay JA, Frechet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005; 23: 1517-26.
63. Kostarelos K. The long and short of carbon nanotube toxicity. Nat Biotechnol 2008; 7: 774-5.
64. Lacerda L, Soundararajan A, Singh R et al. Dynamic imaging of functionalized multi-walled carbon nanotube systemic circulation and urinary excretion. Adv Mater 2008; 20: 225-30.
65. Thakor AS, Jokerst J, Zavaleta C, Massoud TF, Gambhir SS. Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett 2011; 11: 4029-36.
66. Chauhan VP, Popović Z, Chen O et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed 2011; 50: 11417-20.
67. Chu KS, Hasan W, Rawal S et al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomed Nanotechnol Biol Med 2013; 9: 686-93.
68. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007; 2: 249-55.
69. Zhou Z, Ma X, Jin E et al. Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery. Biomaterials 2013; 34: 5722-35.
70. Anderson AJ, Robinson JT, Dai H, Hunter AC, Andresen TL, Moghimi SM. Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 2013; 7: 1108-19.
71. Dobrovolskaia MA, Patri AK, Simak J et al. Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm 2012; 9: 382-93.
72. Shcharbin D, Janaszewska A, Klajnert-Maculewicz B et al. How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo. J Control Release 2014; 181: 40-52.
73. Wu W, Driessen W, Jiang X. Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration. J Am Chem Soc 2014; 136: 3145-55.
74. Lagunas A, Castaño AG, Artés JM et al. Large-scale dendrimer-based uneven nanopatterns for the study of local arginine-glycine-aspartic acid (RGD) density effects on cell adhesion. Nano Res 2014; 7: 399-409.
75. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv Drug Deliv Rev 2012; 64: 571-88.
76. Perumal OP, Inapagolla R, Kannan S, Kannan RM. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterals 2008; 29: 3469-76.
77. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem 2006; 17: 275-83.
78. Tang MX, Redemann CT, Szoka FC. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 1996; 7: 703-14.
79. Liu X, Wu J, Yamine M et al. Structurally flexible triethanolamine core PAMAM dendrimers are effective nanovectors for DNA transfection in vitro and in vivo to the mouse thymus. Bioconjug Chem 2011; 22: 2461-73.
80. Boreham A, Pfaff M, Fleige E, Haag R, Alexiev U. Nanodynamics of dendritic core-multishell nanocarriers. Langmuir 2014; 30: 1686-95.
81. Freitas RA Jr. Shapes and metamorphic surfaces. Nanomedicine, Vol I: Basic Capabilities. Georgetown, TX: Landes Bioscience, 1999.
82. Reebye V, Sætrom PI, Mintz PJ et al. A novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis invivo. Hepatology 2014; 59: 216-27.
83. Mignami S, El Kazzouli S, Bousmina M, Majoral J-P. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev 2013; 65: 1316-30.
84. Tomalia DA. Dendritic effects: dependency of dendritic nano-periodic property patterns on critical nanoscale design parameters (CNDPs). New J Chem 2012; 36: 264-81.
85. Tomalia DA, Baker H, Dewald J et al. A new class of polymers: starburst dendritic macromolecules. Polym J (Tokyo) 1985; 17: 117-32.
86. Tomalia DA, Fréchet JMJ. Discovery of dendrimers and dendritic polymers: a brief historical perspective. J Polym Sci A Polym Chem 2002; 40: 2719-28.
87. Rosen BM, Wilson CJ, Wilson DA, Peterca M, Imam MR, Percec V. Dendron-mediated self-assembly, disassembly, and self-organization of complex systems. Chem Rev 2009; 109: 6275-540.
88. Lim J, Simanek EE. Triazine dendrimers as drug delivery systems: from synthesis to therapy. Adv Drug Deliv Rev 2012; 64: 826-35.
89. Jain S, Kaur A, Puri R et al. Poly propyl ether imine (PETIM) dendrimer: a novel non-toxic dendrimer for sustained drug delivery. Eur J Med Chem 2010; 45: 4997-5005.
90. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today 2001; 6: 427-36.
91. Chen H, Banaszak Holl M, Orr B, Majoros I, Clarkson BH. Interaction of dendrimers (artificial proteins) with hydroxyapatite crystals. J Dent Res 2003; 82: 443-8.
92. Wong C-H, Zimmerman SC. Orthogonality in organic, polymer, and supramolecular chemistry: from Merrifield to click chemistry. Chem Commun 2013; 49: 1679-95.
93. Lothian-Tomalia MK, Hedstrand DM, Tomalia DA. A contemporary survey of covalent connectivity and complexity. The divergent synthesis of poly(thioether) dendrimers. Amplified, genealogical directed synthesis leading to the de gennes dense packed state. Tetrahedron 1997; 53: 15495-513.
94. Padias AB, Hall HK Jr, Tomalia DA, McConnell JR. Starburst polyether dendrimers. J Org Chem 1987; 52: 5305-12.
95. Iha RK, Wooley KL, Nystrom AM, Burke DJ, Kade MJ, Hawker CJ. Applications of orthogonal "click" chemistries in the synthesis of functional soft materials. Chem Rev 2009; 109: 5620-86.
96. Hourani R, Sharma A, Kakkar A. Designing dendritic frameworks using versatile building blocks suitable for CuI-catalyzed alkyne azide click chemistry. Tetrahedron Lett 2010; 51: 3792-5.
97. Tomalia DA, Huang B, Swanson DR, Brothers HM II, Klimash JW. Structure control within poly(amidoamine) dendrimers: size, shape and regio-chemical mimicry of globular proteins. Tetrahedron 2003; 59: 3799-813.
98. Walter MV, Malkoch M. Simplifying the synthesis of dendrimers: accelerated approaches. Chem Soc Rev 2012; 41: 4593-609.
99. Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005; 30: 294-324.
100. Yang D, Yu L, Van S. Clinically relevant anticancer polymer paclitaxel therapeutics. Cancers 2011; 3: 17-42.
101. Rios-Doria J, Carie A, Costich T et al. A versatile polymer micelle drug delivery system for encapsulation and in vivo stabilization of hydrophobic anticancer drugs. J Drug Deliv 2012; 2012: 1-8.
102. Ramireddy RR, Raghupathi KR, Torres DA, Thayumanavan S. Stimuli sensitive amphiphilic dendrimers. New J Chem 2012; 36: 340-9.
103. Dougherty CA, Furgal JC, Van Dongen MA et al. Isolation and characterization of precise dye/dendrimer ratios. Chem Eur J 2014; 20: 1-9.
104. Karton-Lifshin N, Shabat D. Exponential diagnostic signal amplification via dendritic chain reaction: the dendritic effect of a self-immolative amplifier component. New J Chem 2012; 36: 386-93.
105. Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJH. Cationic poly-l-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm 2006; 3: 614-27.
106. Yang Y, Sunoqrot S, Stowell C et al. Effect of size, surface charge, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromolecules 2012; 13: 2154-62.
107. El Kazzouli S, Mignami S, Bousmina M, Majoral J-P. Dendrimer therapeutics: covalent and ionic attachments. New J Chem 2012; 36: 227-40.
108. Olson ES, Jiang T, Aguilera TA et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc of the National Acad of Sci 2010; 107: 4311-6.
109. Ma X, Zhao Y, Liang XJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res 2011; 44: 1114-22.
110. Svenson S. Theranostics: are we there yet? Mol Pharm 2012; 10: 848-56.
111. Lo S-T, Kumar A, Hsieh J-T, Sun X. Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm 2013; 10: 793-812.
112. Key J, Leary JF. Nanoparticles for multimodal in vivo imaging in nanomedicine. Int J Nanomed 2014; 9: 711-26.
113. Taratula O, Schumann C, Naleway MA, Pang AJ, Chon KJ. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Mol Pharm 2013; 10: 3946-58.
114. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem 2011; 22: 1879-903.
115. Santra S, Kaittanis C, Santiesteban OJ, Perez JM. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. J Am Chem Soc 2011; 133: 16680-8.
116. Pan D. Special issue: theranostic nanomedicine with functional nanoarchitecture. Mol Pharm 2013; 10: 781-1150.
117. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc of the National Acad of Sci 2004; 101: 17867-72.
118. Nguyen QT, Olson ES, Aguilera TA et al. Surgery with molecular fluorescence imaging using activable cell-penetrating peptides decreases residual cancer and improves survival. Proc of the National Acad of Sci 2010; 107: 4317-22.
119. Olson ES, Whitney MA, Friedman B et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol 2012; 4: 595-605.
120. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005; 57: 2215-37.
121. Gardikis K, Micha-Screttas M, Demetzos C, Steele BR. Dendrimers and the development of new complex nanomaterials for biomedical applications. Curr Med Chem 2012; 19: 4913-28.
122. Khandare J, Calderon M, Dagia MN, Haag R. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem Soc Rev 2012; 41: 2824-48.
123. Ma N, Ma C, Deng Y, Wang T, He N. Advances in applications of dendritic compounds. J Nanosci Nanotechnol 2013; 19: 33-9.
124. Thomas TP, Goonewardena SN, Majoros IJ et al. Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum 2011; 63: 2671-80.
125. Gerard HC, Mishra MJ, Mao G et al. Dendrimer-enabled DNA delivery and transformation of Chlamydia pneumoniae. Nanomed Nanotechnol Biol Med 2013; 9: 996-1008.
126. Kannan RM, Gerard HC, Mishra MK et al. Dendrimer-enabled transformation of Chlamydia trachomatis. Microb Pathog 2013; 65: 29-35.
127. Hayder M, Poupot M, Baron M et al. A phosphorus-based dendrimer targets inflammation and dosteoclastogenesis in experimental arthritis. Sci Transl Med 2011; 2011: 81ra35.
128. Chauhan AS, Jain NK, Diwan PV, Khopade AJ. Solubility enhancement of indomethacin using dendrimer complex and bio-disposition profile of these complexes in arthiritic rats. J Drug Target 2004; 12: 575-83.
129. Chauhan AS, Diwan PV, Jain NK, Tomalia DA. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules 2009; 10: 1195-202.
130. Inapagolla R, Guru BR, Kurtoglu KE et al. In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation. Int J Pharm 2010; 399: 140-7.
131. Blattes E, Vercellone A, Eutamène H et al. Mannodendrimers prevent acute lung inflammation by inhibiting neutrophil recruitment. Proc Natl Acad Sci USA 2013; 110: 8795-800.
132. Iezzi R, Guru BR, Glybina IV, Mishra MJ, Kennedy A, Kannan RM. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012; 33: 979-88.
133. Kannan S, Dai H, Navath RS et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 2012; 4: 130ra46.
134. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999; 10: 767-76.
135. Kaminskas LM, McLeod VM, Kelly BD et al. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Mol Pharm 2012; 9: 422-32.
136. Jiang YY, Tang G-T, Zhang L-H, Kong S-Y, Zhu S-J, Pei Y-Y. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J Drug Target 2010; 18: 389-403.
137. Zhang L, Zhu S, Qian L, Pei Y, Qiu Y, Jiang Y. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Eur J Pharm Biopharm 2011; 79: 232-40.
138. Gajbhiye V, Jain NK. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2011; 32: 6213-25.
139. Ly TU, Tran NQ, Hoang TKD, Phan KN, Truong HN, Nguyen CK. Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. J Biomed Nanotechnol 2013; 9: 213-20.
140. Singh P, Gupta U, Asthana A, Jain NK. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug deliery potential in tumor bearing mice. Bioconjug Chem 2008; 19: 2239-52.
141. Fox ME, Guillaudeu S, Fréchet JMJ, Jerger K, Macaraeg N, Szoka FC. Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates. Mol Pharm 2009; 6: 1562-672.
142. Sato N, Kobayashi H, Saga T et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice1. Clin Cancer Res 2001; 7: 3606-12.
143. Vincent L, Varet J, Pille J-Y et al. Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies. Int J Cancer 2003; 105: 419-29.
144. Koppu S, Oh YJ, Edrada-Ebel RA et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J Control Release 2010; 143: 215-21.
145. Shaunak S, Thomas S, Gianasi E et al. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004; 22: 977-84.
146. Wang B, Navath RS, Menjoge AR et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int J Pharm 2010; 395: 298-308.
147. Landers JJ, Cao Z, Lee I et al. Prevention of influenza pneumonitis by sialic acid conjugated dendritic polymers. J Infect Dis 2002; 186: 1222-30.
148. Kumar PV, Agashe H, Dutta T, Jain NK. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr Drug Deliv 2007; 4: 11-9.
149. ®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 2011; 6: e24095.
150. Zhou J, Neff CP, Liu X et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiciently suppresses HIV-1 infection in humanized mice. Mol Ther 2011; 19: 2228-38.
151. Kobayashi H, Sato N, Hiraga A et al. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmokinetic properties. Magn Reson Med 2001; 45: 454-60.
152. Kobayashi H, Sato N, Kawamoto S et al. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. Bioconjug Chem 2001; 12: 100-7.
153. Sato N, Kobayashi H, Hiraga A et al. Pharmacokinetics and enhancement of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn Reson Med 2001; 46: 1169-73.
154. Criscione JM, Dobrucki LW, Papademetris X, Simons M, Sinusas AJ, Fahmy TA. Development and application of a multimodal contrast agent for SPECT/CT hybrid imaging. Bioconjug Chem 2011; 22: 1784-92.
155. 64Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic placque. Bioconjug Chem 2014; 25: 231-9.
156. Castelli DD, Terreno E, Longo D, Aime S. Nanoparticle-based chemical exchange saturation transfer (CEST) agents. NMR Biomed 2013; 26: 839-49.
157. Pikkemaat JA, Wegh RT, Lamerichs R et al. Dendritic PARACEST contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging 2007; 2: 229-39.
158. Ali MM, Liu G, Shah T, Flask CA, Pagel MD. Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies. Acc Chem Res 2009; 42: 915-24.
159. Koc FE, Senel M. Solubility enhancement of non-steroidal anti-inflammatory drugs (NSAIDs) using polypolypropylene oxide core PAMAM dendrimers. Int J Pharm 2013; 451: 18-22.
160. Neibert K, Gosein V, Sharma A et al. Click dendrimers as anti-inflammatory agents: with insights into their binding from molecular modeling studies. Mol Pharm 2013; 10: 2502-8.
161. Mishra MK, Beaty CA, Lesniak WG et al. Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest. ACS Nano 2014; 8: 2134-47.
162. Dai H, Navath RS, Balakrishnan B et al. Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. Nanomedicine (Lond) 2010; 5: 1317-29.
163. Albertazzi L, Gherardini L, Brondi M et al. In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol Pharm 2013; 10: 249-60.
164. Projan SJ. Whither antibacterial drug discovery? Drug Discovery Today 2008; 13: 279-80.
165. Castonguay A, Ladd E, van de Ven TGM, Kakkar A. Dendrimers as bactericides. New J Chem 2012; 36: 199-204.
166. Chen CZ, Cooper SL. Interactions between dendrimer biocides and bacterial membranes. Biomaterials 2002; 23: 3359-68.
167. Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011; 40: 173-90.
168. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT. Dendrimer - silver complexes and nanocomposites as antimicrobial agents. Nano Lett 2001; 1: 18-21.
169. Mintzer MA, Dane EL, O'Toole GA, Grinstaff MW. Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol Pharm 2012; 9: 342-54.
170. Lazniewska J, Milowska K, Gabryelak T. Dendrimers-revolutionary drugs for infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012; 4: 469-91.
171. Choi SK, Myc A, Silpe JE et al. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano 2013; 7: 214-28.
172. Teo I, Toms SM, Marteyn B et al. Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers. EMBO Mol Med 2012; 4: 866-81.
173. Bhadra D, Bhadra S, Jain NK. PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm Res 2006; 23: 623-33.
174. Bernstein DI, Stanberry LR, Sacks S et al. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother 2003; 47: 3784-8.
175. Jiang YH, Emau P, Cairns JS et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2005; 21: 207-13.
176. Supattapone S, Piro JR, Rees JR. Complex polyamines: unique prion disaggregating compounds. CNS Neurol Disord Drug Targets 2009; 8: 323-8.
177. McCarthy JM, Moreno BR, Filippini D et al. Influence of surface groups on poly(propylene imine) dendrimers antiprion activity. Biomacromolecules 2013; 14: 27-37.
178. McCarthy JM, Rasines B, Appelhans D, Rogers M. Differentiating prion strains using dendrimers. Adv Healthc Mater 2012; 1: 768-72.
179. McCarthy JM, Appelhans D, Tatzelt J, Rogers MS. Nanomedicine for prion disease treatment: new insights into the role of dendrimers. Prion 2013; 7: 198-202.
180. Klajnert B, Cangiotti M, Calici S et al. Interactions between dendrimers and heparin and their implications for the anti-prion activity of dendrimers. New J Chem 2009; 33: 1087-93.
181. Shiao TC, Roy R. Glycodendrimers as functional antigens and antitumor vaccines. New J Chem 2012; 36: 324-39.
182. Kaminskas LM, McLeod VM, Ryan GM et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release 2014; 183: 18-26.
183. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009; 109: 49-87.
184. Cheng Y, ed. Dendrimer-Based Drug Delivery Systems. Hoboken, NJ: Wiley. 2012.
185. Boas U, Christensen JB, Heegaard PMH. Dendrimers in Medicine and Biotechnology. Cambridge, UK: The Royal Society of Chemistry, 2006.
186. Navarro G, Maiwald G, Haase R et al. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. J Control Release 2010; 146: 99-105.
187. Jiao AL, Slack FJ. RNA-mediated gene activation. Epigenetics 2014; 9: 1-10.
188. Klajnert B, Peng L, Cena V, eds. Dendrimers in Biomedical Applications. Cambridge, UK: RSC Publishing, 2013.
189. Grinstaff MW. Designing hydrogel adhesives for corneal wound repair. Biomaterials 2007; 28: 5205-14.
190. Berdahl JP, Johnson CS, Proia AD, Grinstaff MW, Kim T. Compression of sutures and dendritic polymer adhesitves for cornial laceration repair in an in vivo chicken model. Arch Ophthalmol 2009; 127: 442-7.
191. Johnson CS, Wathier M, Grinstaff MW, Kim T. In vitro sealing of clear corneal cataract incisions with a novel biodendrimer adhesive. Arch Ophthalmol 2009; 127: 430-4.
192. Velazquez AJ, Carnahan MA, Kristinsson J, Stinnett S, Grinstaff MW, Kim T. New dendritic adhesives for sutureless ophthalmic surgical procedures. Arch Ophthalmol 2004; 122: 867-70.
193. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol 2009; 127: 1043-7.
194. Chaplot SP, Rupenthal ID. Dendrimers for gene delivery - a potential approach for ocular therapy? J Pharm Pharmacol 2013; 66: 542-56.
195. Oliveira JM, Salgado AJ, Sousa N, Mano JF. Dendrimers and derivatives as a potential therapeutic tool in regenerative medicine strategies - a review. Prog Polym Sci 2010; 35: 1163-94.
196. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano 2012; 6: 7595-606.
197. Kambhampati SP, Kannan RM. Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther 2013; 29: 151-65.
198. Yavuz B, Pehlivan SB, Unlu N. Dendrimeric systems and their applications in ocular drug delivery. Scientific World Journal 2013; 2013: 1-13.
199. Dobrovolskaia MA, McNeil SE, eds. Handbook of Immunological Properties of Engineered Nanomaterials. Vol. 1 in Frontiers in Medical Research. Hackensack, NJ: World Scientific, 2013.
200. Monteiro-Riviere NA, Tran CL, eds. Nanotoxicology: Characterization, Dosing, and Health Effects. New York, NY: Informa Healthcare USA. 2007.
201. Anderson PW. More is different. Science 1972; 177: 393-6.
202. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010; 394: 122-42.
203. Kaminskas LM, Boyd BJ, Porter CJH. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine (Lond) 2011; 6: 1063-84.
204. Nel A, Xia T, Meng H et al. Nanomateral toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Acc Chem Res 2013; 46: 607-21.
205. Tomalia DA, Christensen JB, Boas U. A quantized building block concept leading to a new nano-periodic system. In: Dendrimers, Dendrons, and Dendritic Polymers: Discovery, Applications and the Future. New York, NY: Cambridge University Press, 2012; 293-377.
206. Kobayashi H, Kawamoto S, Saga T et al. Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generatioin of polyamidoamine dendrimer core: reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J Magn Reson Imaging 2001; 14: 705-13.
207. Tomalia DA, Christensen JB, Boas U. Toxicology of dendrimers and dendrons. In: Dendrimers, dendrons, and dendritic polymers: discovery, applications and the future. New York, NY: Cambridge University Press, 2012; 255-75.
208. Pearson RM, Sunoqrot S, Hsu H-J, Bae JW, Hong S. Dendritic nanoparticles: the next generation of nanocarriers? Ther Deliv 2012; 3: 941-59.
209. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008; 3: 703-17.
210. Malik N, Wiwattanapatapee R, Klopsch R et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125 l-labelled polyamidoamine dendrimers in vivo. J Control Release 2000; 65: 133-48.
211. Tomalia DA, Christensen JB, Boas U. Nanomedical and advanced materials. In: Dendrimers, Dendrons, and Dendritic Polymers: Discovery, Applications and the Future. New York, NY: Cambridge University Press, 2012; 187-254.
212. Jones CF, Campbell RA, Brooks BD, Ghandehari H, Grainger DW. Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano 2012; 6: 9900-10.
213. Jones CF, Campbell RA, Franks Z et al. Cationic PAMAM dendrimers disrupt key platelet functions. Mol Pharm 2012; 9: 1599-611.
214. Greish K, Thiagarajan G, Herd H et al. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 2010; 6: 713-23.
215. Parrott MC, Benhabbour SR, Saab C et al. Synthesis, radiolabeling, and bio-imaging of high-generation polyester dendrimers. J Am Chem Soc 2009; 131: 2906-16.
216. Kojima C, Regino CAS, Umeda Y, Kobayashi H, Kono K. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 2010; 383: 293-6.
217. Kojima C, Turkbey B, Ogawa M et al. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomed Nanotechnol Biol Med 2011; 7: 1001-8.
218. Nel AE. Implementation of alternative test strategies for the safety assessment of engineered nanomaterials. J Int Med 2013; 274: 561-77.
219. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 2006; 311: 622-7.
220. Collins FS, Gray GM, Butcher JR. Toxicology. Transforming environmental health protection. Science 2008; 319: 906-7.
221. Hartung T. Toxicology for the twenty-first century. Nature 2009; 460: 208-12.
222. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 2010; 267: 89-105.
223. Jacobson KA. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). Bioconjug Chem 2009; 20: 1816-35.
224. Patra S, Kozura B, Huang AY-T et al. Dendrimers terminated with dichlorotrizine groups provide a route to compositional diversity. Org Lett 2013; 15: 3808-11.
225. Fadeel B. Nanosafety: towards safer design of nanomedicines. J Intern Med 2013; 274: 578-80.
226. Onoue S, Yamada S, Chan H-K. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine 2014; 9: 1025-37.
227. Moghimi SM, Peer D, Langer R. Reshaping the future of nanopharmaceuticals: ad Iudicium. ACS Nano 2011; 5: 8454-8.
228. Tomalia DA. Periodic patterns, relationships and categories of well-defined nanoscale building blocks. National Science Foundation Final Workshop Report, 2008; 1-156. Available at: http://www.nsf.gov/crssprgm/nano/GC_Charact08_Tomalia_nsf9_29_08.pdf.